HNB
ENTA icon

Huntington National Bank’s Enanta Pharmaceuticals ENTA Stock Holding History

Huntington National Bank’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-137
Closed -$2.93K – 3854
2023
Q2 		$2.93K Buy
+137
New +$4.04K ﹤0.01% 1958

Other funds holding ENTA

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Huntington National Bank's ENTA Position: Q3 2023 in Review

Huntington National Bank sold out of Enanta Pharmaceuticals (ENTA) in Q3 2023, closing a stake of 137 shares — an estimated $2.93K sold.

Huntington National Bank first reported a position in ENTA in Q2 2023 and held it in 1 quarter. The position peaked at $2.93K in Q2 2023. 133 funds tracked by Wall St. Rank hold ENTA as of Q3 2023.

  • Huntington National Bank reported no remaining Enanta Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Huntington National Bank sold 137 Enanta Pharmaceuticals shares in Q3 2023, an estimated $2.93K.
  • Huntington National Bank first reported a position in Enanta Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • Huntington National Bank's Enanta Pharmaceuticals position peaked at $2.93K in Q2 2023.
  • 133 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2023.

Based on Huntington National Bank's 13F filing for Q3 2023, filed 8 Nov 2023.